Latest Content

FDA boosts DT120 lysergide ODT after phase 3 shows lasting depression relief; psychedelic tablet also advances for anxiety and other brain disorders.

Experts unpack screening for sexual dysfunction in psychiatric care, menopause and meds impacts, and when flibanserin may help restore desire.

Learn how to spot and treat sexual dysfunction in psychiatric care—screen causes, manage SSRI effects, and choose libido-friendly medications.

Pramipexole was associated with improvement in anhedonia and apathy, and with increased physical activity in patients with mood disorders, in a placebo-controlled trial that measured both behavioral and neurophysiologic change.

Public health professional Shambrekia Wise and her daughter Sandy discuss the origins of their travel-themed book series and its relevance to clinicians treating diverse young patients.

Discuss depression care challenges, comorbidities, and new treatments—submit cases, research, or CME ideas for Psychiatric Times’ September 2026 series.

Review the developments in GLP-1s in 2026.

A target trial emulation of more than 1.5 million matched adults ties GLP-1 RA initiation to lower mortality and cardiovascular events in serious mental illness.

New trial shows edible THC worsens lane control and reaction time at low blood levels, raising doubts about current legal impairment limits.

Yale trio-genomics study links hair-pulling and skin-picking to inherited OCD risk scores and rare DNA variants, hinting at shared brain pathways.

International Overdose Awareness Day marks 25 years, spotlighting fragile declines in deaths and urging naloxone access, harm reduction funding, and stigma-free care.

Much of what we call "treatment-resistant" depression may be mismatched, not resistant. A psychiatrist makes the case for trading the failed-drug tally for a difficult-to-treat framework clinicians can act on Monday morning.

BioVie completes treatment visits in a phase 2 long COVID trial of bezisterim targeting brain fog and fatigue, with topline results expected September 2026.